Drug Type Universal CAR-T, Induced pluripotent stem cells (iPSC) |
Synonyms- |
Target |
Mechanism 4-1BB inhibitors(Tumor necrosis factor receptor superfamily member 9 inhibitors), BCMA inhibitors(B-cell maturation protein inhibitors), CD58 inhibitors(Lymphocyte function-associated antigen 3 inhibitors) |
Therapeutic Areas |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Leukemia | Preclinical | US | 08 Dec 2024 | |
Lymphoma | Preclinical | US | 08 Dec 2024 |